<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147225</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0099</org_study_id>
    <nct_id>NCT00147225</nct_id>
  </id_info>
  <brief_title>AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin</brief_title>
  <official_title>Phase I/II Study of AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest safe dose of AMG 531 that
      will decrease the risk and severity of thrombocytopenia (low platelet counts) in patients who
      have received chemotherapy. Researchers will also look at the safety and effectiveness of AMG
      531 (Romiplostim).

      Primary Objectives:

        1. To determine the clinical safety and tolerability of AMG 531 administered following
           chemotherapy in patients with advanced malignancy

        2. To determine an optimal biologic dose (OBD) of AMG 531 administered in patients
           receiving chemotherapy known to cause severe thrombocytopenia

        3. To evaluate the effects of AMG 531 on the degree and duration of thrombocytopenia and
           platelet recovery following chemotherapy

      Secondary Objective:

      1. To evaluate limited pharmacokinetics of AMG 531 administered by S.C. route
      post-chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelets are cells that help make the blood clot. A decrease in platelets can cause
      bleeding, which may prevent or delay a patient from receiving chemotherapy. Researchers want
      to find out if AMG 531 can lower the risk and severity of this side effect. AMG 531 is a
      protein that stimulates platelet production.

      If you are eligible to take part in this study, you will be assigned to 1 of 6 dosing
      schedules of study drug. The dose of AMG 531 that you receive will depend on when you are
      enrolled.

      In Cycle 1, all patients will receive chemotherapy by itself. Three (3) weeks later, in Cycle
      2, the same dose of chemotherapy will be given followed by AMG 531. AMG 531 will be given on
      one of 3 schedules. AMG 531 will be given as an injection under the skin on the day after
      chemotherapy and 2 days later; it will be given 5 days before and the day after chemotherapy;
      or it will be given 5 and 3 days before chemotherapy and on the day after chemotherapy and 2
      days later. The schedule you receive will depend on when you enroll on the study. After 2
      cycles of treatment, based on response of the disease and tolerance to the treatment, all
      participants may be able to receive up to 4 more cycles of chemotherapy followed by AMG 531.
      All participants will continue on the same schedule you were receiving before. The dose of
      AMG 531 may be increased at one time point during the study based on the response of the
      platelet counts.

      The number of blood tests drawn (about 3 teaspoons each) will depend on your clinical
      condition. These samples will be taken at least 2 times a week and as often as once a day
      during portions of the study. You will also have blood (about 1 teaspoon) collected for the
      evaluation of anti-AMG 531 antibody status before treatment starts, at the end of Cycles 2
      and 4, and at the end of study.

      You will be taken off the study if your disease gets worse or intolerable side effects occur.
      At the end of the study, you will have a medical history and physical exam, including
      measurement of vital signs. You will also have blood (about 1 teaspoon) drawn for routine
      tests.

      This is an investigational study. AMG 531 is not FDA approved or commercially available. At
      this time, it is being used for research purposes only. Up to 56 patients will take part in
      this study. All will be enrolled at University of Texas (UT)MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy</measure>
    <time_frame>Toxicity assessments with each dose level/cycle (21-28 day cycle) up to 6 cycles</time_frame>
    <description>Number of participants experiencing an adverse event (AE) or serious adverse event (SAE) during study treatment, possible or probable related to study drug. All toxicities graded using the Common Terminology Criteria for Adverse Events version 3.0. Participation has a maximum of 6 cycles of chemotherapy on the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Venous Thromboembolism (VTE) Related Serious Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy</measure>
    <time_frame>Toxicity assessments with each dose level/cycle (21-28 day cycle) up to 6 cycles</time_frame>
    <description>Number of participants experiencing an venous thromboembolism (VTE) related serious adverse event (SAE) during study treatment, possible or probable related to study drug. All toxicities graded using the Common Terminology Criteria for Adverse Events version 3.0. Participation has a maximum of 6 cycles of chemotherapy on the study. VTE events reported are part or whole total number reported for study SAEs, not in addition to SAEs reported.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>1 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
Adriamycin - Ifosfamide (AI) regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg/kg Pre/Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy (Control Cycle); Beginning Cycle 2, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy (post dose) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mcg/kg AMG 531 + Pre/Pre/Post/Post Chemotherapy Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 531</intervention_name>
    <description>Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).
1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)</description>
    <arm_group_label>1 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg Pre/Post Chemotherapy</arm_group_label>
    <arm_group_label>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <other_name>Romiplostim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.</description>
    <arm_group_label>1 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg Pre/Post Chemotherapy</arm_group_label>
    <arm_group_label>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>75-90 mg/m^2 IV</description>
    <arm_group_label>1 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg Pre/Post Chemotherapy</arm_group_label>
    <arm_group_label>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>10 gm/m^2 IV; OR, High dose ifosfamide = 14 gm/m^2.</description>
    <arm_group_label>1 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>3 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg AMG 531 Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg Pre/Post Chemotherapy</arm_group_label>
    <arm_group_label>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <arm_group_label>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a diagnosis of solid tumors who are at high risk for
             chemotherapy-induced severe thrombocytopenia related to the following regimens: (a)
             Carboplatin (AUC=11); (b) AI regimen (adriamycin 75-90mg/m2, Ifosfamide 10gm/m2); (c)
             High dose Ifosfamide (14gm/m2)

          2. Age &gt;/= 18 years.

          3. Adequate hematologic (Absolute neutrophil count (ANC) &gt;/= 1500/mm^3, platelet count
             &gt;/= 100 x 10^9/L and Hgb &gt;/= 8 gm/dL), renal (serum creatinine &lt;/= 2.0 mg/dL), and
             hepatic functions (total bilirubin &lt;/= 2 times, aspartate aminotransferase (AST or
             SGOT) or alanine aminotransferase (ALT or SGPT) &lt;/= 3 times the upper limit of the
             respective normal range).

          4. Karnofsky Performance Status &gt;/= 80

          5. Signed informed consent form

          6. Patients with childbearing potential (defined as not post-menopausal for 12 months or
             no previous surgical sterilization) must have a negative pregnancy test and use
             adequate birth control. [i.e. oral contraceptives, spermicide with either a condom,
             diaphragm or cervical cap, use of an intrauterine device (IUD), or abstinence].

        Exclusion Criteria:

          1. Patients with rapidly progressive disease (such as patients with rapidly accumulating
             ascites or pleural effusion).

          2. Patients with hematologic malignancies.

          3. Pregnant or lactating women.

          4. History of central nervous system (CNS) metastasis.

          5. Patients with significant cardiac disease (New York Hearth Association (NYHA) Class
             III or IV), dysrrhythmia, or recent history of MI or ischemia, transient ischemic
             attack or cerebrovascular accident (CVA), within the previous 6 months of study entry.

          6. Patients with a history of thromboembolic events (history of deep venous thrombosis
             (DVT) or pulmonary embolus).

          7. Prior chemotherapy, immunotherapy, or experimental drug (not FDA-approved drug) within
             3 weeks. Patients will be eligible if day 1 of chemotherapy was initiated 3 weeks
             prior to study entry if the patient has recovery of blood counts and from acute
             toxicity of chemotherapy as described in inclusion criteria # 3.

          8. Use of nitrosourea (carmustine (BCNU), lomustine (CCNU) or mitomycin - C within 6
             weeks of study entry.

          9. Prior surgery or Radiation Therapy (RT) within 2 weeks of study entry.

         10. Patients with history of prior whole pelvic radiation will be excluded unless there is
             no prior history of severe thrombocytopenia (i.e. platelet nadir &lt;10,000/mm^3)

         11. Patients with history of prior high dose chemotherapy with stem cell transplant or
             with history of prolonged thrombocytopenia (&gt;/= 2 weeks).

         12. History of any platelet disorders including Idiopathic thrombocytopenic purpura (ITP),
             Thrombotic thrombocytopenic purpura (TTP) or bleeding disorders.

         13. History of &gt; 4 prior chemotherapy regimens (all platinum regimens will be counted as
             one regimen).

         14. Patients with significant bowel dysfunction secondary to tumor (significant abdominal
             pain with severe constipation/diarrhea (&gt;/= Grade 3), significant difficulty
             maintaining oral nutrition).

         15. Patients with pre-existing neuropathy &gt; Grade 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan-Raj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>April 7, 2014</results_first_submitted>
  <results_first_submitted_qc>April 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2014</results_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancer</keyword>
  <keyword>Advanced Malignancy</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>AMG 531</keyword>
  <keyword>Romiplostim</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paraplatin</keyword>
  <keyword>Platelets</keyword>
  <keyword>Adriamycin</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Rubex</keyword>
  <keyword>Ifosfamide</keyword>
  <keyword>Ifex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 08/04/05 to 04/09/12. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 55 participants enrolled, one participant was enrolled but was a screen failure and another three withdrew without receiving any study drug thus were excluded from the trial demographics.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 mcg/kg AMG 531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
Adriamycin /Ifosfamide (AI) regimens [Adriamycin (Doxorubicin) 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2</description>
        </group>
        <group group_id="P2">
          <title>3 mcg/kg AMG 531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
        </group>
        <group group_id="P3">
          <title>10 mcg/kg AMG 531 Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
        </group>
        <group group_id="P4">
          <title>10 mcg/kg Pre/Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy (Control Cycle); Beginning Cycle 2, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy (post dose) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
        </group>
        <group group_id="P5">
          <title>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
        </group>
        <group group_id="P6">
          <title>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
          <description>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.
Chemotherapy :
Carboplatin [area under the concentration curve (AUC) = 11]; or
AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
High dose Ifosfamide: 14 gm/m^2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Chemotherapy Changed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by AMG 531 subcutaneously of 21-28 day treatment cycle. There were 51 participants who received at least one dose of the study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>1 mcg/kg AMG 531 Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
        </group>
        <group group_id="B2">
          <title>3 mcg/kg AMG 531 Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
        </group>
        <group group_id="B3">
          <title>10 mcg/kg AMG 531 Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
        </group>
        <group group_id="B4">
          <title>10 mcg/kg Pre/Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy</description>
        </group>
        <group group_id="B5">
          <title>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses)</description>
        </group>
        <group group_id="B6">
          <title>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="10"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="27" upper_limit="60"/>
                    <measurement group_id="B2" value="50" lower_limit="23" upper_limit="67"/>
                    <measurement group_id="B3" value="31" lower_limit="24" upper_limit="63"/>
                    <measurement group_id="B4" value="37" lower_limit="19" upper_limit="59"/>
                    <measurement group_id="B5" value="46" lower_limit="33" upper_limit="61"/>
                    <measurement group_id="B6" value="49" lower_limit="20" upper_limit="62"/>
                    <measurement group_id="B7" value="43" lower_limit="19" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy</title>
        <description>Number of participants experiencing an adverse event (AE) or serious adverse event (SAE) during study treatment, possible or probable related to study drug. All toxicities graded using the Common Terminology Criteria for Adverse Events version 3.0. Participation has a maximum of 6 cycles of chemotherapy on the study.</description>
        <time_frame>Toxicity assessments with each dose level/cycle (21-28 day cycle) up to 6 cycles</time_frame>
        <population>All participants who received treatment were evaluable for toxicity; therefore 51 participants who received at least one dose of the study drug were evaluable for toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mcg/kg AMG 531 Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
          </group>
          <group group_id="O2">
            <title>3 mcg/kg AMG 531 Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
          </group>
          <group group_id="O3">
            <title>10 mcg/kg AMG 531 Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
          </group>
          <group group_id="O4">
            <title>10 mcg/kg Pre/Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy</description>
          </group>
          <group group_id="O5">
            <title>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses)</description>
          </group>
          <group group_id="O6">
            <title>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy</title>
          <description>Number of participants experiencing an adverse event (AE) or serious adverse event (SAE) during study treatment, possible or probable related to study drug. All toxicities graded using the Common Terminology Criteria for Adverse Events version 3.0. Participation has a maximum of 6 cycles of chemotherapy on the study.</description>
          <population>All participants who received treatment were evaluable for toxicity; therefore 51 participants who received at least one dose of the study drug were evaluable for toxicity.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events, Possible or Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events, Possible or Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Venous Thromboembolism (VTE) Related Serious Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy</title>
        <description>Number of participants experiencing an venous thromboembolism (VTE) related serious adverse event (SAE) during study treatment, possible or probable related to study drug. All toxicities graded using the Common Terminology Criteria for Adverse Events version 3.0. Participation has a maximum of 6 cycles of chemotherapy on the study. VTE events reported are part or whole total number reported for study SAEs, not in addition to SAEs reported.</description>
        <time_frame>Toxicity assessments with each dose level/cycle (21-28 day cycle) up to 6 cycles</time_frame>
        <population>All participants who received treatment were evaluable for toxicity; therefore 51 participants who received at least one dose of the study drug were evaluable for toxicity.</population>
        <group_list>
          <group group_id="O1">
            <title>1 mcg/kg AMG 531 Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
          </group>
          <group group_id="O2">
            <title>3 mcg/kg AMG 531 Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
          </group>
          <group group_id="O3">
            <title>10 mcg/kg AMG 531 Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
          </group>
          <group group_id="O4">
            <title>10 mcg/kg Pre/Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy</description>
          </group>
          <group group_id="O5">
            <title>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses)</description>
          </group>
          <group group_id="O6">
            <title>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
            <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Venous Thromboembolism (VTE) Related Serious Adverse Events in Sequential Cohort Dose Escalation Study of AMG 531 Following Chemotherapy</title>
          <description>Number of participants experiencing an venous thromboembolism (VTE) related serious adverse event (SAE) during study treatment, possible or probable related to study drug. All toxicities graded using the Common Terminology Criteria for Adverse Events version 3.0. Participation has a maximum of 6 cycles of chemotherapy on the study. VTE events reported are part or whole total number reported for study SAEs, not in addition to SAEs reported.</description>
          <population>All participants who received treatment were evaluable for toxicity; therefore 51 participants who received at least one dose of the study drug were evaluable for toxicity.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulmonary Embolism (PE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Vein Thrombosis (DVT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total VTE Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events reported once the participant received their first dose of study drug, AMG 531 in Cycle 2 up to 6 cycles. Cycles were 21 to 28 days. The total study period was from August 5, 2005 to May 11, 2012.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 mcg/kg AMG 531 Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
        </group>
        <group group_id="E2">
          <title>3 mcg/kg AMG 531 Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
        </group>
        <group group_id="E3">
          <title>10 mcg/kg AMG 531 Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later</description>
        </group>
        <group group_id="E4">
          <title>10 mcg/kg Pre/Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy</description>
        </group>
        <group group_id="E5">
          <title>5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses)</description>
        </group>
        <group group_id="E6">
          <title>10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy</title>
          <description>Cycle 1: Chemotherapy
Cycle 2: Chemotherapy, 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytosis (&gt;/= 1,000,000/mm^3)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flu-Like Symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain, Bone</sub_title>
                <description>Also includes back pain, neck pain or extremity pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cramp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin/rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Saroj Vadhan-Raj</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-7966</phone>
      <email>svadhanr@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

